Effects of Dorzolamide on Retinal and Choroidal Blood Flow in the DBA/2J Mouse Model of Glaucoma

Chandra, Saurav; Muir, Eric R.; Deo, Kaiwalya S; Kiel, Jeffrey W.; Duong, Timothy Q.

doi:10.1167/iovs.15-18291

Cited by 17 publications

(14 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For instance, melatonin or its analogue 5-MCA-NAT reduced IOP between 29 and 32% in the DBA/2J and, as happened in the present paper, the effect on the normotensive animal was not so marked [27]. Other authors who used classical compounds such as the carbonic anhydrase inhibitor dorzolamide have demonstrated a similar effect [28], reducing IOP. These authors observed reductions of approximately 60%, which are far from the ones here described.…”

Section: Discussionsupporting

confidence: 81%

Diadenosine tetraphosphate as a potential therapeutic nucleotide to treat glaucoma

Fonseca

Martínez-Águila

Lara

et al. 2016

Purinergic Signalling

View full text Add to dashboard Cite

Glaucoma is a neurodegenerative disease that produces blindness. The main factor associated with this disease is an abnormally elevated intraocular pressure (IOP). To date, some attempts have been made to demonstrate the role of nucleotides modulating IOP, but never in a model of glaucoma. The DBA/2J mouse is an animal that develops the pathology spontaneously, starting from the typical rise in IOP at 9 months of age. Using this animal model, together with a control mouse, C57BL/6J, it has been possible to monitor the elevation in IOP in the glaucomatous mice and to check the ability of the dinucleotide diadenosine tetraphosphate AKA Ap 4 A to reduce IOP. The topical application of Ap 4 A when IOP is maximal (9-12 months) reduced IOP 30.6 ± 6.6% in the DBA/2J and 17.9 ± 4.0% in the C57BL/ 6J mice. Concentration response curves in both animal strains produced similar pD2 values; these being 4.9 ± 0.5 and 5.1 ± 0.4 for the normotensive C57BL/6J and the glaucomatous DBA/2J respectively. Antagonist studies showed differences between the control and the glaucomatous animals. In particular, the main receptor reducing IOP in the control animal was the P2Y 1 receptor and in the glaucomatous model the P2Y 6 , although the participation of other P2 receptors cannot be ruled out. The long-term effect of Ap 4 A applied three times a week for 3 months showed a clear stop in the elevation of IOP in the glaucomatous model, thus indicating the possibility of using Ap 4 A as an effective compound for the treatment of glaucoma.

show abstract

Section: Discussionsupporting

confidence: 81%

Diadenosine tetraphosphate as a potential therapeutic nucleotide to treat glaucoma

Fonseca

Martínez-Águila

Lara

et al. 2016

Purinergic Signalling

View full text Add to dashboard Cite

show abstract

“…Apart from lowering intraocular pressure, the drugs used in glaucoma therapy may additionally improve blood perfusion in the eye (87). Such an effect is caused by carbonic anhydrase inhibitors (88). An improvement in ocular circulation was also noted in the case of latanoprost (89,90).…”

Section: Neuroprotection To Counteract Vascular Deregulationmentioning

confidence: 86%

Neuroprotection to Counteract Glaucomatous Degeneration of Retina; The Use of Citicoline

Kozera¹,

Rękas²

2019

Acta Poloniae Pharmaceutica - Drug Research

View full text Add to dashboard Cite

Glaucoma is a chronic degenerative disease affecting the optic nerve that causes a loss of retinal ganglion cells and their axons. Glaucomatous neuropathy constitutes a worldwide health problem. Every ophthalmologist working at a hospital or at an outpatient clinic sees patients with glaucoma, and thus information about the pathomechanisms responsible for its development, about its treatment and about new therapeutic options constitutes valuable knowledge for all ophthalmology practitioners. It is widely known that the better the mechanisms of disease development are known, the easier it is to effectively inhibit disease progression. Therefore, researchers are continuing their studies on pathophysiology and effective treatment, which have been moving from the macroscopic to the microscopic level as new methods become available. And thus, over years of conducted studies, the neuroprotective effect of citicoline was noted. Known to neurologists, this substance is now entering the pharmacological world of ophthalmologists. This article discusses the role and possibilities of neuroprotective treatment of glaucoma, emphasising the scientifically proven effects of citicoline, which seems to be a new trend supporting the drug treatment used to date.

show abstract

“…At the same time, the main focus of our current study was on the age- and IOP-related changes in the same animals, or animals from the same species. While both direct and indirect comparisons of D2 and B6 mice have been used in this and other MRI- and non-MRI based studies of visual pathway changes 17 , 24 , 30 , 70 – 78 , future studies should also consider comparing D2 mice with the age- and genetically-matched DBA/2J-Gpnmb+/SjJ mice, both male and female. On the other hand.…”

Section: Discussionmentioning

confidence: 99%

Age-related Changes in Eye, Brain and Visuomotor Behavior in the DBA/2J Mouse Model of Chronic Glaucoma

Yang

Merwe

Sims

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Although elevated intraocular pressure (IOP) and age are major risk factors for glaucoma, their effects on glaucoma pathogenesis remain unclear. This study examined the onset and progression of glaucomatous changes to ocular anatomy and physiology, structural and physiological brain integrity, and visuomotor behavior in the DBA/2J mice via non-invasive tonometry, multi-parametric magnetic resonance imaging (MRI) and optokinetic assessments from 5 to 12 months of age. Using T2-weighted MRI, diffusion tensor MRI, and manganese-enhanced MRI, increasing IOP elevation at 9 and 12 months old coincided with anterior chamber deepening, altered fractional anisotropy and radial diffusivity of the optic nerve and optic tract, as well as reduced anterograde manganese transport along the visual pathway respectively in the DBA/2J mice. Vitreous body elongation and visuomotor function deterioration were observed until 9 months old, whereas axial diffusivity only decreased at 12 months old in diffusion tensor MRI. Under the same experimental settings, C57BL/6J mice only showed modest age-related changes. Taken together, these results indicate that the anterior and posterior visual pathways of the DBA/2J mice exhibit differential susceptibility to glaucomatous neurodegeneration observable by in vivo multi-modal examinations.

show abstract

Effects of Dorzolamide on Retinal and Choroidal Blood Flow in the DBA/2J Mouse Model of Glaucoma

Cited by 17 publications

References 45 publications

Diadenosine tetraphosphate as a potential therapeutic nucleotide to treat glaucoma

Diadenosine tetraphosphate as a potential therapeutic nucleotide to treat glaucoma

Neuroprotection to Counteract Glaucomatous Degeneration of Retina; The Use of Citicoline

Age-related Changes in Eye, Brain and Visuomotor Behavior in the DBA/2J Mouse Model of Chronic Glaucoma

Contact Info

Product

Resources

About